These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma. Imam SZ; Zahid MF; Maqbool MA Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):168-170. PubMed ID: 29684339 [TBL] [Abstract][Full Text] [Related]
6. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Díaz-González Á; Sanduzzi-Zamparelli M; Sapena V; Torres F; LLarch N; Iserte G; Forner A; da Fonseca L; Ríos J; Bruix J; Reig M Aliment Pharmacol Ther; 2019 Mar; 49(5):482-491. PubMed ID: 30695819 [TBL] [Abstract][Full Text] [Related]
7. Psoriasiform drug eruption secondary to sorafenib: case series and review of the literature. Ensslin CJ; Kao PH; Wu MY; Chang YY; Kuo TT; Hsieh CH; Hsieh SY; Yang CH; Miller LS Cutis; 2019 Sep; 104(3):E11-E15. PubMed ID: 31675404 [TBL] [Abstract][Full Text] [Related]
8. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients. Chang WT; Lu SN; Rau KM; Huang CS; Lee KT Kaohsiung J Med Sci; 2018 Jul; 34(7):391-399. PubMed ID: 30063012 [TBL] [Abstract][Full Text] [Related]
9. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. Eilard MS; Andersson M; Naredi P; Geronymakis C; Lindnér P; Cahlin C; Bennet W; Rizell M BMC Cancer; 2019 Jun; 19(1):568. PubMed ID: 31185950 [TBL] [Abstract][Full Text] [Related]
10. Polymyalgia rheumatica occurrence under multikinase inhibitors (sorafenib and erlotinib) treatment. Verhoeven F; Weil-Verhoeven D; Prati C; Di Martino V; Wendling D Joint Bone Spine; 2019 Oct; 86(5):663-664. PubMed ID: 30928535 [No Abstract] [Full Text] [Related]
11. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. Brunetti O; Gnoni A; Licchetta A; Longo V; Calabrese A; Argentiero A; Delcuratolo S; Solimando AG; Casadei-Gardini A; Silvestris N Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31640191 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib. da Fonseca LG; Marta GN; Braghiroli MIFM; Chagas AL; Carrilho FJ; Hoff PM; Sabbaga J BMC Cancer; 2018 Dec; 18(1):1250. PubMed ID: 30545331 [TBL] [Abstract][Full Text] [Related]
14. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. Tovoli F; Ielasi L; Casadei-Gardini A; Granito A; Foschi FG; Rovesti G; Negrini G; Orsi G; Renzulli M; Piscaglia F J Hepatol; 2019 Dec; 71(6):1175-1183. PubMed ID: 31449860 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination. El Shorbagy S; abuTaleb F; Labib HA; Ebian H; Harb OA; Mohammed MS; Rashied HA; Elbana KA; Haggag R J Gastrointest Cancer; 2021 Mar; 52(1):269-279. PubMed ID: 32212089 [TBL] [Abstract][Full Text] [Related]
16. Sorafenib-induced erythema annulare centrifugum with spontaneous resolution after skin biopsy. Yao CA Australas J Dermatol; 2018 May; 59(2):e150-e151. PubMed ID: 28726329 [No Abstract] [Full Text] [Related]
17. Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib. Yamamoto K; Kuzuya T; Honda T; Ito T; Ishizu Y; Nakamura M; Miyahara R; Kawashima H; Ishigami M; Fujishiro M Anticancer Res; 2020 Feb; 40(2):665-676. PubMed ID: 32014907 [TBL] [Abstract][Full Text] [Related]
18. Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients. Ruanglertboon W; Sorich MJ; Rowland A; Hopkins AM Int J Clin Oncol; 2020 Sep; 25(9):1672-1677. PubMed ID: 32417993 [TBL] [Abstract][Full Text] [Related]
19. Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. Brandi G; De Lorenzo S; Di Girolamo S; Bellentani S; Saccoccio G; Biasco G Tumori; 2015 Apr; 101(2):e46-8. PubMed ID: 25702656 [TBL] [Abstract][Full Text] [Related]
20. pH-responsive hyaluronic acid nanoparticles coloaded with sorafenib and cisplatin for treatment of hepatocellular carcinoma. Zhang W; Cai J; Wu B; Shen Z J Biomater Appl; 2019 Aug; 34(2):219-228. PubMed ID: 31084233 [No Abstract] [Full Text] [Related] [Next] [New Search]